Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation
Edward Rothstein, Wikke Walop(Public Health Agency of Canada), Sandra Jo Hammer(California Department of Public Health), Jerry Labadie(Netherlands Pharmacovigilance Centre Lareb), Scott A. Halperin(Dalhousie University), Patricia Vermeer(National Institute for Public Health and the Environment), Paul T. Heath(St George's, University of London), Katrin Kohl(Centers for Disease Control and Prevention), Cynthia Kleppinger(United States Food and Drug Administration), Frederick Varricchio(Rutgers, The State University of New Jersey), L. Ball(Center for Biologics Evaluation and Research), Renald Hennig(Novartis (Germany)), Neal A. Halsey(Johns Hopkins University)
Cited by 48
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses
|Clinical Infectious Diseases|2017|453
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System
|The Pediatric Infectious Disease Journal|2004|381
The changing and dynamic epidemiology of meningococcal disease
|Vaccine|2011|304